MX2023006573A - Constructos de inmunoglobulina con multiples dominios de union. - Google Patents
Constructos de inmunoglobulina con multiples dominios de union.Info
- Publication number
- MX2023006573A MX2023006573A MX2023006573A MX2023006573A MX2023006573A MX 2023006573 A MX2023006573 A MX 2023006573A MX 2023006573 A MX2023006573 A MX 2023006573A MX 2023006573 A MX2023006573 A MX 2023006573A MX 2023006573 A MX2023006573 A MX 2023006573A
- Authority
- MX
- Mexico
- Prior art keywords
- immunoglobuline
- constructs
- binding domains
- multiple binding
- additionally
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Se describen nuevos formatos de moléculas multiespecíficas, así como sus métodos de fabricación. Además, también se describen usos en indicaciones terapéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063121166P | 2020-12-03 | 2020-12-03 | |
PCT/US2021/061587 WO2022120033A1 (en) | 2020-12-03 | 2021-12-02 | Immunoglobuline constructs with multiple binding domains |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023006573A true MX2023006573A (es) | 2023-06-19 |
Family
ID=79170974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023006573A MX2023006573A (es) | 2020-12-03 | 2021-12-02 | Constructos de inmunoglobulina con multiples dominios de union. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4255931A1 (es) |
JP (1) | JP2023553384A (es) |
KR (1) | KR20230117397A (es) |
CN (1) | CN116783217A (es) |
AU (1) | AU2021393456A1 (es) |
CA (1) | CA3203468A1 (es) |
IL (1) | IL303205A (es) |
MX (1) | MX2023006573A (es) |
WO (1) | WO2022120033A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023218027A1 (en) * | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
DE19650370A1 (de) | 1996-12-05 | 1998-06-10 | Basf Ag | Flammwidrige thermoplastische Formmassen auf der Basis von Polyarylenethern |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Cd19×cd3特異的ポリペプチドおよびその使用 |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
EP3569610A3 (en) | 2000-12-12 | 2020-03-18 | Medlmmune, LLC | Molecules with extended half lives, compositions and uses thereof |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
JP5105874B2 (ja) | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合因子 |
SI1673398T1 (sl) | 2003-10-16 | 2011-05-31 | Micromet Ag | Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule |
AU2005229009A1 (en) | 2004-03-23 | 2005-10-13 | Amgen, Inc. | Monoclonal antibodies specific for human OX40L (CD 134L) |
JP2008512987A (ja) | 2004-07-22 | 2008-05-01 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 結合分子 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR100609578B1 (ko) | 2004-12-28 | 2006-08-08 | 주식회사 하이닉스반도체 | 플래쉬 메모리소자의 플로팅 게이트전극 형성방법 |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
AU2007219159B8 (en) | 2006-01-25 | 2012-06-28 | Roger Kingdon Craig | Generation of heavy-chain only antibodies in transgenic animals |
ES2432792T5 (es) | 2007-04-03 | 2023-01-16 | Amgen Res Munich Gmbh | Dominio de unión a CD3-épsilon específico de especies cruzadas |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
GB0706628D0 (en) | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
CN112680475A (zh) | 2008-12-18 | 2021-04-20 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
JP2021521275A (ja) * | 2018-04-13 | 2021-08-26 | アフィメド ゲーエムベーハー | Nk細胞結合抗体融合構築物 |
-
2021
- 2021-12-02 WO PCT/US2021/061587 patent/WO2022120033A1/en active Application Filing
- 2021-12-02 IL IL303205A patent/IL303205A/en unknown
- 2021-12-02 CN CN202180081858.3A patent/CN116783217A/zh active Pending
- 2021-12-02 AU AU2021393456A patent/AU2021393456A1/en active Pending
- 2021-12-02 EP EP21835502.2A patent/EP4255931A1/en active Pending
- 2021-12-02 CA CA3203468A patent/CA3203468A1/en active Pending
- 2021-12-02 MX MX2023006573A patent/MX2023006573A/es unknown
- 2021-12-02 JP JP2023533306A patent/JP2023553384A/ja active Pending
- 2021-12-02 KR KR1020237022372A patent/KR20230117397A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023553384A (ja) | 2023-12-21 |
WO2022120033A1 (en) | 2022-06-09 |
IL303205A (en) | 2023-07-01 |
CA3203468A1 (en) | 2022-06-09 |
AU2021393456A1 (en) | 2023-06-29 |
EP4255931A1 (en) | 2023-10-11 |
KR20230117397A (ko) | 2023-08-08 |
CN116783217A (zh) | 2023-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
CR20200571A (es) | Moléculas de únion contra bcma y usos de las mismas | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
NZ754051A (en) | Novel antibodies and uses thereof | |
PH12015501134B1 (en) | Egfr and c-met-fibronectin type iii domain binding molecules | |
MX2019010583A (es) | Anticuerpos contra ligando 1 de muerte programada. | |
MX2018002933A (es) | Pigmentos casi infrarrojos (nir) dirigidos por antígeno de membrana específico de próstata (psma) y sus usos. | |
MX2017000187A (es) | Proteinas de union a cd33 y cd3 biespecificas. | |
MX2012004210A (es) | Derivados de pirazol como moduladores del canal de calcio activado por liberacion de calcio. | |
BR112022004047A2 (pt) | Proteínas de ligação multiespecíficas para o tratamento de câncer | |
PH12019502602A1 (en) | Polypeptides antagonizing wnt signaling in tumor cells | |
AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
MX2022010515A (es) | Conjugacion mediada por transglutaminasa. | |
MX2021015337A (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. | |
MX2011011075A (es) | Anticuerpos especificos para cadherina-17. | |
MX2023006573A (es) | Constructos de inmunoglobulina con multiples dominios de union. | |
MX2021004732A (es) | Anticuerpos de cadena pesada que se unen a cd38. | |
MX2021014164A (es) | Moleculas de union a cd19 y usos de las mismas. | |
CR20230398A (es) | Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3 | |
MX2021003180A (es) | Métodos y kits para preparar sangre entera con inactivación de patógenos. | |
WO2022217123A3 (en) | Combination therapies with cbl-b inhibitor compounds | |
MX2022007613A (es) | Union de anticuerpos de cadena pesada a cd38. | |
MX2023001109A (es) | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. | |
WO2019023315A3 (en) | RAC INHIBITORS | |
MX2022001428A (es) | Metodos y composiciones para cultivar bacterias dependientes de hemoglobina. |